Eosinophils, pruritus and psoriasis: Effects of treatment with etretinate or cyclosporin-A

Journal of the European Academy of Dermatology and Venereology

Volumn 11, Issue 3, 1998, Pages 234-239

  Schopf, R E ^a,c   Hultsch, T ^a   Lotz, J ^a   Brautigam M ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cyclosporin A; Eosinophil cationic protein; Eosinophils; Etretinate; Pruritus; Psoriasis

Indexed keywords

CYCLOSPORIN A; ETRETIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EOSINOPHIL; HUMAN; LEUKOCYTE ACTIVATION; PRIORITY JOURNAL; PRURITUS; PSORIASIS;

BLOOD PROTEINS; CYCLOSPORINE; DERMATOLOGIC AGENTS; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILS; ETRETINATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; KERATOLYTIC AGENTS; LEUKOCYTE COUNT; PRURITUS; PSORIASIS; RIBONUCLEASES;

EID: 0032420326     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(98)00084-1     Document Type: Article

References (26)

1. Sehgal VN, Srivastava G. Exfoliative dermatitis. A prospective study of 80 patients. Dermatologica 1986; 173:278-284.
2. Lundin Å Fredens K, Michaelsson G, Venge P. The eosinophil granulocyte in psoriasis. Br J Dermatol 1990;122:181-193.
3. Juhlin L, Venge P. Eosinophilic cationic protein (ECP) in skin disorders. Acta Derm Venereol (Stockh) 1991;71:495-501.
4. Tsuge I, Fujii H, Andou Y, Katayama I, Kajita M, Haga Y, Asano K, Mori O, Matsumoto Y, Ohashi M. A case of infantile febrile psoriasiform dermatitis. Pediatr Dermatol 1995;12:28-34.
5. Kim TY, Park HJ, Kim CW. Eosinophil cationic protein (ECP) level and its correlation with eosinophil number or IgE level of peripheral blood in patients with various skin diseases. J Dermatol Sci 1997;15:89-94.
6. Michaelsson G, Kraaz W, Gerden B, Hagforsen E, Lundin IP, Loof L, Sjoberg O, Scheynius A. Patients with psoriasis have elevated levels of serum eosinophil cationic protein and increased numbers of EG2 positive eosinophils in the duodenal stroma. Br J Dermatol 1996;135:371-378.
7. Sklianskaia OA, Miagkova LP, Ivashkin VT, Lapina TL. Possible combination of eosinophilic infiltration of the stomach, small and large intestines with psoriasis. Arkh Patol 1997;59:54-58.
8. Thomson AW, Milton JI, Aldridge RJL. Inhibition of drug-induced eosinophilia by cyclosporin A. Scand J Immunol 1986;24:163-170.
9. Etienne A, Soulard C, Thonier F. Modulation by drugs of eosinophil recruitment induced by immune challenge in the rat. Possible roles of interleukin-5 and platelet-activating factor. Int Arch Allergy Appl Immunol 1989;88:216-221.
10. Shupack JL, Kenny C, Jondreau L, Eckman I, Gropper C, Stiller MJ. Decreased peripheral blood eosinophil counts in severe psoriatic patients treated with low-dose cyclosporine A. Dermatology 1992;185:202-204.
11. Müller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
12. Ellis CN, Fadin MS, Messana JM, Brown MK, Siegel MT, Hartley H, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooper KD, Voorhees JJ. Cyclosporine for plaque-type psoriasis. N Engl J Med 1991;324:277-284.
13. Schopf RE, Höcher J, Schütz N, Färber L, Morsches B. Psoriasis treatment with etretinate versus cyclosporin A. Clinical course and serum concentrations of soluble interleukin-2 receptors and CD8 antigen. Eur J Dermatol 1992;2:224-230.
14. Hess AD, Colomabani PM. Mechanism of action of cyclosporin: in vitro studies. In: Borel JF, editor. Cyclosporin. Prog Allerg Basel: Karger, 1986;38:198-221.
15. Valdimarsson H, Baker BS, Jónsdóttir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986;7:256-259.
16. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venerol (Stockh) 1990;70:323-329.
17. Kaplan RP, Russel DH, Lowe NJ. Etretinate therapy for psoriasis: clinical responses. J Am Acad Dermatol 1983;8:95-102.
18. Shapiro PE, Edelson RL. Effects of retinoids on the immune system. In: Saurat JH, editor. Retinoids: New Trends in Research and Therapy. Basel: Karger, 1985:225-235.
19. Orfanos CE, Bauer R. Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol 1983;109 Suppl. 25:55-60.
20. Fredricksson, T., Pettersson, U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 78;157:238-244.
21. Janeway CA, Travers P. Immunobiology, 3rd edn. London: Current Biology, 1997.
22. Sperr WR, Agis H, Semper H, Valenta R, Susani M, Sperr M, Willheim M, Scheiner O, Liehl E, Lechner K, Valent P. Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. Int Arch Allergy Immunol 1997;114:68-73.
23. Oppenheim JJ, Ruscetti FW. Cytokines. In: Stites DP, Terr AI, Parslow TG, editors. Medical Immunology 9th edn. Stamford, CT: Appleton and Lange, 1997:146-168.
24. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745-748.
25. Terr AI. Inflammation. In: Stiles DP, Terr AI, Parslow TG, editors. Medical Immunology, 9th edn. Stamford, CT: Appleton and Lange, 1997:182-195.
26. Steigleder GK, Inderwisch R. Eosinophilic leucocytes in the skin lesions of psoriasis and atopic dermatitis Arch Derm Res 1975;254:253-255.